Sleep Cycle: A Record B2B Quarter, a CEO Swap, and a Music Deal That Changes Everything
The consumer app is shrinking, the margin is cost-cut, and a share-funded acquisition of Audiowell would remake the company before Apnea Alert launches.
SLEEP.ST · Earnings Call · 2026-10-23
The quarter that changed the story
Sleep Cycle's Q3 was not a clean beat. It was a company in transition, and the transition is now bigger than the app. Revenue fell 12% currency-adjusted as new consumer subscriptions weakened, and paying subscribers were down 24% year over year. Management pinned the decline on falling organic traffic, not churn: renewals held, and ARPU rose 5% to SEK 282 on price increases. The offset was B2B revenue, which reached a record SEK 10 million, almost 20% of the total, up almost 50%. “Q3, it was a quarter of record B2B revenue, a leaner organization, and we have proposed to acquire Audiowell” — Mikael Kågebäck, Acting CEO and CTO · 2026-10-23. That sentence is the whole report: the old consumer engine is shrinking, the licensing engine is growing, and the company is asking shareholders to approve a deal that would change what Sleep Cycle is.
The B2C business remains under pressure, while the B2B revenue is continuing to grow and reached a record SEK 10 million this quarter, almost 20% of the total revenue.
The company is also still pre-launch on its most important new product. Apnea Alert, its contactless sleep apnea risk detector, is now planned for the EU and UK in early 2027 under MDR Class I. More than 150,000 people have registered interest, and management sizes the addressable market at around SEK 25 billion. That is a credible option, but it is not yet revenue.
A margin built on less marketing
The profitability story is better than the headline. Adjusted EBIT was SEK 15.1 million, a 29.7% margin, versus roughly 27% a year earlier. Reported EBIT was only SEK 1.1 million because the quarter carried about SEK 14 million of one-offs for the CEO change and the new organization. Strip those out and personnel costs were SEK 11.2 million, almost a fifth lower than last year; marketing was cut by about a third, deliberately, to fix onboarding before stepping back up. “Our top line is still under pressure, with net sales falling 12%, currency adjusted.” — Elisabeth Hedman, CFO and Head of Investor Relations · 2026-10-23 The margin is real, but it is being bought with cost discipline, not operating leverage.
Management says the reorganization removes around 15 positions and ends several consultancy contracts, producing about SEK 35 million of annual savings. “We have reduced the organization by around 15 positions and ended several consultancy contracts and external services.” — Elisabeth Hedman, CFO and Head of Investor Relations · 2026-10-23 Full-year adjusted EBIT margin is guided to around 20%, with Q4 around 30%; the reported margin lands near 7% after one-offs. The obvious question is durability. Redeye asked how much of the improvement came from lower marketing, fewer consultants, and higher capitalization of development costs. Management declined to forecast: “We will not give a prognosis or forecast of the margin” — Elisabeth Hedman, CFO and Head of Investor Relations · 2026-10-23. That is fair, but it leaves the market to guess how much of the 30% Q3 margin is seasonal and how much is structural.
The Audiowell acquisition is the real story
The Audiowell acquisition is the reason this quarter matters. Audiowell is an independent Stockholm record label and music publisher for sleep and relaxation music, founded in 2013. Sleep Cycle proposes to pay in shares, with an EGM on November 11 and closing expected in Q4. The combined 2025 business is pitched at SEK 625 million of net sales, SEK 282 million of EBIT, and a 45% profit margin. For context, that net sales figure is larger than Sleep Cycle's current market capitalization of roughly SEK 490 million. This is not a bolt-on; it is a transformational share-funded combination that would turn a sleep-app company into a sleep-and-wellbeing content platform.
The governance change is just as striking. Audiowell CEO Gustav Forssell is intended to become group CEO, while acting CEO and CTO Mikael Kågebäck would become CTO of the new group. “If the deal goes through, Audiowell CEO, Gustav Forssell, is intended as CEO of the group, and I will take the role of CTO in the new group.” — Mikael Kågebäck, Acting CEO and CTO · 2026-10-23 Management argues for clear synergies between music streaming and Sleep Cycle's sleep-aid feature, plus new revenue in apps, streaming, and white-label solutions. The strategic logic is easy to state: Sleep Cycle has sleep analysis, distribution, and 2.5 million yearly active users; Audiowell has a catalog and a profitable music business. The risk is equally easy to state: shareholders are being asked to approve a share-funded acquisition, a CEO transition, and a new corporate identity while the core consumer business is still shrinking.
Apnea Alert, licensing, and a company-unique bet
The health bet is not a global wave. The market's top keywords this quarter are dominated by tariffs, AI data centers, Fed rate hikes, and supply chains. No other recent reporter is talking about contactless sleep or sleep apnea as a platform. That makes Sleep Cycle's story company-unique, which is both an opportunity and a warning: there is no sector tape to lift the stock if execution slips.
The licensing pillar is the bridge. tech licensing is now about 20% of revenue and the fastest-growing part. In Q3, Ultrahuman converted a pilot into a commercial SDK license, Ant Group signed for China, and Moera launched a mattress with Sleep Cycle's analysis running on-device. “Moera is a recurring revenue. It is a multi-year contract” — Elisabeth Hedman, CFO and Head of Investor Relations · 2026-10-23, management said, which helps the B2B run rate but does not fully answer how much is one-off versus recurring across the portfolio. The UKHSA cough-data research is an interesting public-health option, but it is still a pilot discussion, not a revenue line.
What to watch
The next six weeks are binary. The November 11 EGM decides whether Sleep Cycle becomes a profitable music-and-wellbeing group with a sleep-tech option, or remains a cost-cut app company waiting for Apnea Alert in 2027. Near term, watch whether Q4 actually prints the guided ~30% adjusted margin, whether the new organization's savings show up without another revenue air pocket, and whether paying subscribers stabilize as onboarding and win-back offers roll out. The tape offers no help: no price history was provided, so there is no drawdown or breakout to lean on. The story is entirely fundamental — and unusually, it hinges on a shareholder vote rather than a product launch.